Cara Mathews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cara Mathews has a total of 505 co-authors. Here are the top co-authors by number of shared publications:
- Shannon Neville Westin
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
13 shared publications - Amanda M. Nash
Department of Bioengineering, Rice University, Houston, TX, USA
12 shared publications - Amir Anthony Jazaeri
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
12 shared publications - Amy J. Bregar
Massachusetts General Hospital, Boston, MA, USA
12 shared publications - Andrew M. Blakely
Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
12 shared publications - Bryan Fellman
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
12 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Manual describing preparation and administration of cell product
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Manual describing preparation and administration of cell product
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Long-Term Tracking of Eosinophil and Lymphocyte Counts Post-Treatment, related to Figure 4. (A) Total eosinophil and (B) lymphocyte count quantified serially for the duration of study (Day 0 - 120) post-treatment (n = 2 per group). Data are expressed as mean ± SEM.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Long-Term Tracking of Eosinophil and Lymphocyte Counts Post-Treatment, related to Figure 4. (A) Total eosinophil and (B) lymphocyte count quantified serially for the duration of study (Day 0 - 120) post-treatment (n = 2 per group). Data are expressed as mean ± SEM.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Manufacturing timeline for drug product development. Schematic illustration showing RPE cell expansion, two parallel batched harvests generating two encapsulation runs each, and the corresponding timelines.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Manufacturing timeline for drug product development. Schematic illustration showing RPE cell expansion, two parallel batched harvests generating two encapsulation runs each, and the corresponding timelines.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Assessment of model performance with all parameters as random effect variables, related to Figure 2. A) Comparison of experimental data to population model predictions. B) Comparison of experimental data to individual model predictions. Blue curves: linear regression of individual points.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Assessment of model performance with all parameters as random effect variables, related to Figure 2. A) Comparison of experimental data to population model predictions. B) Comparison of experimental data to individual model predictions. Blue curves: linear regression of individual points.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Empirical Bayes estimates of individual λ values in final model, related to Figure 2. X-axis is given in terms of difference from population value in log space (η). Colors represent different dose levels (DL).
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Empirical Bayes estimates of individual λ values in final model, related to Figure 2. X-axis is given in terms of difference from population value in log space (η). Colors represent different dose levels (DL).
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Waterfall plot. Related to Figure 1. Best response change from baseline (% change, n=14) per response evaluation criteria in solid tumors (RECIST v.1.1) by cohort, calculated based on sum of diameters for target lesions. Value above each bar represents dose cohort. (1- 0.6 ug/kg/day; 2- 1.2 ug/kg/day; 3- 2.4 ug/kg/day; 4- 3.6 ug/kg/day).
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Waterfall plot. Related to Figure 1. Best response change from baseline (% change, n=14) per response evaluation criteria in solid tumors (RECIST v.1.1) by cohort, calculated based on sum of diameters for target lesions. Value above each bar represents dose cohort. (1- 0.6 ug/kg/day; 2- 1.2 ug/kg/day; 3- 2.4 ug/kg/day; 4- 3.6 ug/kg/day).
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Assessment of model performance with only λ as a random effect variable, related to Figure 2. A) Comparison of experimental data to population model predictions. B) Comparison of experimental data to individual model predictions. Blue curves: linear regression of individual points.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Assessment of model performance with only λ as a random effect variable, related to Figure 2. A) Comparison of experimental data to population model predictions. B) Comparison of experimental data to individual model predictions. Blue curves: linear regression of individual points.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Longitudinal analysis of CBC and liver function post-treatment. (A) Total eosinophil (B) platelet and (C) lymphocyte counts quantified at days 0, 2, 4, 8, 15, 22, and 29 post-treatment (n = 3–5 per group). (D) Liver function assessed through the analysis of AST, ALT, and GGT levels over time at the same intervals (n = 3–5 per group). Data are expressed as mean ± SEM.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Longitudinal analysis of CBC and liver function post-treatment. (A) Total eosinophil (B) platelet and (C) lymphocyte counts quantified at days 0, 2, 4, 8, 15, 22, and 29 post-treatment (n = 3–5 per group). (D) Liver function assessed through the analysis of AST, ALT, and GGT levels over time at the same intervals (n = 3–5 per group). Data are expressed as mean ± SEM.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
. IL2 linearity, related to Figure 2. Each dose of AVB-001 administered resulted in a proportional, linear increase in serum IL2 levels. Data are presented as mean ± SEM.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
. IL2 linearity, related to Figure 2. Each dose of AVB-001 administered resulted in a proportional, linear increase in serum IL2 levels. Data are presented as mean ± SEM.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-10 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Collated supplementary tables 1-10 and supplementary text
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-10 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Collated supplementary tables 1-10 and supplementary text